Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients

Једноставна страница ставке
dc.citation.spage6275987
dc.citation.volume2017
dc.contributor.authorLukic, Ruzica
dc.contributor.authorGajovic, Nevena
dc.contributor.authorJovanovic, Ivan
dc.contributor.authorJurisevic, Milena
dc.contributor.authorMijailovic, Zeljko
dc.contributor.authorMaric, Veljko
dc.contributor.authorPopovska Jovicic, Biljana
dc.contributor.authorArsenijevic, Nebojsa
dc.date.accessioned2023-08-29T12:31:17Z
dc.date.available2023-08-29T12:31:17Z
dc.date.issued2017
dc.description.abstractHepatitis C virus infection (HCV), one of the greatest causes of liver disease, is a frequent complication in patients with end-stage renal disease (ESRD) on dialysis. ESRD is defined as decreased glomerular filtration and also accompanied by impaired function of the immune system. Galectin-3 is a β-galactoside-binding lectin, involved in various biological processes including pathogenesis of chronic renal disease. The aim of our study was to estimate disease severity in ESRD HCV+ patients and analyze the serum concentrations of IL-1β, IL-4, IL-23, and IL-6; anti-HCV antibodies; and galectin-3. Also, we attempted to determine potential correlation between galectin-3 level and parameters of disease severity ALT and AST. Our results showed decreased levels of ALT and AST (p = 0 00), demonstrating less liver destruction in ESRD HCV+ patients in comparison to HCV+ patients. Increased levels of IL-6 (p = 0 03) implicate a hepatoprotective role of IL-6 in these patients. Also, level of galectin-3 (p = 0 00) in the serum of ESRD HCV+ patients was higher than that of HCV+ patients. This alteration was accompanied with negative correlation between galectin-3 and AST and ALT, respectively (p = 0 029; p = 0 033). The presence of increased systemic levels of IL-6 and Gal-3 in ESRD HCV+ patients may be an attempt to counteract or limit ongoing proinflammatory processes and to downregulate chronic inflammation, suggesting the new aspects of HCV infection in ESRD patients.
dc.identifier.doi10.1155/2017/6275987
dc.identifier.urihttps://vaseljena.ues.rs.ba/handle/123456789/604
dc.language.isoen
dc.publisherHindawi
dc.sourceDisease Markers
dc.titlePotential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients
dc.typeArticle
Датотеке
Оригинални завежљај
Сада се приказује 1 - 1 од 1
Сличица
Име:
Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients.pdf
Величина:
1.6 MB
Формат:
Adobe Portable Document Format
Опис:
Преузимање
Свежањ лиценце
Сада се приказује 1 - 1 од 1
Сличица
Име:
license.txt
Величина:
1.71 KB
Формат:
Item-specific license agreed to upon submission
Опис:
Преузимање
Колекције
Медицински факултет [Научни радови] / Faculty of Medicine [Scientific papers]